Last reviewed · How we verify

Astragalus Membranaceus Root

Fujian Medical University Union Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Astragalus Membranaceus Root is a Small molecule drug developed by Fujian Medical University Union Hospital. It is currently FDA-approved.

Astragalus membranaceus root has been studied in clinical trials for various conditions, including lung cancer, urinary incontinence, ischemic stroke, irritable bowel syndrome, and diarrhea-predominant irritable bowel syndrome. However, the mechanism of action of Astragalus membranaceus root is currently unknown, according to ChEMBL.

At a glance

Generic nameAstragalus Membranaceus Root
SponsorFujian Medical University Union Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Astragalus Membranaceus Root

What is Astragalus Membranaceus Root?

Astragalus Membranaceus Root is a Small molecule drug developed by Fujian Medical University Union Hospital.

Who makes Astragalus Membranaceus Root?

Astragalus Membranaceus Root is developed and marketed by Fujian Medical University Union Hospital (see full Fujian Medical University Union Hospital pipeline at /company/fujian-medical-university-union-hospital).

What development phase is Astragalus Membranaceus Root in?

Astragalus Membranaceus Root is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing